Revolutionizing Type 1 Diabetes Treatment: Kyoto University Hospital Pioneers Groundbreaking iPS Cell Clinical Trial
Breakthrough in Type 1 Diabetes Treatment: Kyoto University to Conduct Clinical Trial Using iPS Cells
Researchers at Kyoto University School of Medicine Hospital are making strides in the treatment of type 1 diabetes, a disease caused by immune system abnormalities. The hospital has announced plans to conduct a clinical trial using induced pluripotent stem cells (iPS cells) to create sheets of cells that secrete insulin, which regulates blood sugar levels.
Type 1 diabetes is a chronic condition where the body’s immune system attacks and destroys the cells responsible for producing insulin, a hormone that lowers blood sugar levels. As a result, patients typically require daily insulin injections to manage their condition. In Japan, approximately 140,000 people are affected by this disease.
The clinical trial, set to begin as early as February next year, involves creating clumps of “islet cells of Langerhans” from healthy human iPS cells. These cells will be formed into sheets and transplanted into the abdomen of three patients aged 20 to 65 at Kyoto University Hospital. The islet cell sheets will be provided by a venture company in Fujisawa City, Kanagawa Prefecture.
Professor Daisuke Yabe of the Department of Diabetes, Endocrinology, and Nutrition at Kyoto University’s Graduate School of Medicine expressed optimism about the trial’s potential outcomes. “Our goal is to create a future where patients with type 1 diabetes require fewer insulin injections, and ideally, none at all.”
In contrast to this innovative approach, the current method of extracting islet cells of Langerhans from deceased donors and transplanting them into critically ill patients has been met with limited success in Korea. Despite being covered by public health insurance for the past four years, fewer than 10 patients have received transplants due to a shortage of donors.
The upcoming clinical trial at Kyoto University Hospital offers new hope for patients with type 1 diabetes, and its success could pave the way for more effective treatments in the future.